Blood-Based Markers in Lung Cancer
Harvey I. Pass, MD, discusses blood-based markers in lung cancer.
Harvey I. Pass, MD, Stephen E. Banner Professor of Thoracic Oncology, Vice-Chair Research, Department of Cardiothoracic Surgery, Division Chief, General Thoracic Surgery, NYU Langone Medical Center, discusses blood-based markers in lung cancer.
Pass says the Early Detection Research Network, an NCI-approved group, is handling the research on biomarkers for early detection of lung cancer. The group is looking at blood-based markers, such as micro RNAs and proteomic platforms, in order to try to determine if a nodule on a CT scan is malignant or benign.
Pass says that though there is not a definitive profile, there is a company that is currently commercializing one. However, the sensitivity and specificity of the profile is still not perfect and further tests are being performed.
Clinical Pearls
- The Early Detection Research Network is currently working on a blood-based marker for the early detection of lung cancer
- While there is a company that is commercializing a profile for the early detection of lung cancer, the sensitivity and specificity of the profile is not perfect
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
